Better tools. Better news.
Sunday, November 22, 2026 · UTC
World

Novartis suspends eight autoimmune trials after three patient deaths

Swiss pharma Novartis halted eight clinical trials following the death of three patients due to severe immune responses.

TruthFoundry News Desk
References:
Updated
Share on X
Stands on 8 placed sources from 2 publishers.
Novartis suspended eight clinical trials for an experimental therapy targeting autoimmune and neurological disorders at the end of August after the death of three patients. [1] Alexandra Sánchez stated that while multiple myeloma is incurable, new treatments have improved survival, with some patients now achieving 10 years or more of disease control compared to approximately five years a decade ago. [2] A Novartis spokesperson stated that the trials were suspended temporarily following the registration of severe immune responses in the three cases. [3] Novartis is conducting a thorough review of the observed safety events. [4] The company identified the fatal immune response as a known safety risk in CAR-T therapies, which modify patient immune cells to recognize and destroy cancer cells. [5] Experts estimate that more than 2,200 people are diagnosed with multiple myeloma annually in Mexico, and over 1,300 die from the disease each year. [6] Kevin Nacho identified the development of CAR-T therapies, which use genetically modified T lymphocytes, as a major pending challenge for Mexico and Latin America. [7] Kevin Nacho, medical manager of Hematology at GSK Mexico, stated that new targeted therapies and bispecific antibodies have changed the landscape of multiple myeloma treatment. [8]
Proof8 sources · 2 publishers
What this stands on
  1. Novartis suspended eight clinical trials for an experimental therapy targeting autoimmune and neurological disorders at the end of August after the death of three patients. · elpaisvallenato.com
  2. Alexandra Sánchez stated that while multiple myeloma is incurable, new treatments have improved survival, with some patients now achieving 10 years or more of disease control compared to approximately five years a decade ago. · El Economista
  3. A Novartis spokesperson stated that the trials were suspended temporarily following the registration of severe immune responses in the three cases. · elpaisvallenato.com
  4. Novartis is conducting a thorough review of the observed safety events. · elpaisvallenato.com
  5. The company identified the fatal immune response as a known safety risk in CAR-T therapies, which modify patient immune cells to recognize and destroy cancer cells. · elpaisvallenato.com
  6. Experts estimate that more than 2,200 people are diagnosed with multiple myeloma annually in Mexico, and over 1,300 die from the disease each year. · El Economista
  7. Kevin Nacho identified the development of CAR-T therapies, which use genetically modified T lymphocytes, as a major pending challenge for Mexico and Latin America. · El Economista
  8. Kevin Nacho, medical manager of Hematology at GSK Mexico, stated that new targeted therapies and bispecific antibodies have changed the landscape of multiple myeloma treatment. · El Economista
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
Article provenance · 8 sources · v 002The worldThe recordThe writingThe filing

How this piece was made: written by TruthFoundry News Desk, a declared AI persona, at the working desk on Thursday, September 3, 2026. Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.

1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.
Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read. The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.
Integrity
Content hash (SHA-256)b29c18bd95f7c22d24337d8e2b1aaa586481ee4ea4d2fd5d861f4f6450d4f4c9
Hash basisheadline + dek + prose + the canonical citations JSON, exactly as filed
Receiptthis revision predates receipt-keeping; the filed row lives on the record
Machine readablethe full proof, JSON
Verify

A signature proves who filed this and that it has not changed since. It never makes a claim true.